Malmö University is now further established in the Danish-Swedish life sciences collaboration initiative, Medicon Valley Alliance.

Through a group membership and a seat on the board, the University increases its opportunities to influence research initiatives and the development of strategic cooperation in the Öresund region.

“I see great opportunities going forward. It's about everything from joint research and development initiatives to increased opportunities for international funding,” says Thomas Arnebrant, a professor working at Biofilms Research Center for Biointerfaces.

The Medicon Valley Alliance is an umbrella organisation within life science with the aim of strengthening cooperation between universities, businesses and regions in Sweden and Denmark. Malmö University has been a member since 2009.

“Membership has included discussions with key players around national life science strategies, but also new research collaborations and knowledge transfer between the various actors,” says Arnebrant.

By identifying synergies, new collaborations have emerged. Since 2018, researchers from Malmö University have participated in ReproUnion 2.0, a collaboration on fertility and reproduction, with 14 partners, including Rigshospitalet, Ferring Pharmaceuticals, Copenhagen, and Lund University.

“Malmö University contributes with the social sciences perspective in the project. In the main, researchers from the Centre for Sexology and Sexuality Studies are involved,” says Arnebrant.

Within the framework of deeper cooperation, Malmö University will focus on four areas:

• Drug delivery — with the intention of conducting research on skin, skin conditions, and drug distribution via the skin. This will involve researchers from Biofilms Research Center for Biointerfaces, Biobarriers, and the Skin and Wound Care research platform.

• Diabetes — as of this year, MVA runs a research collaboration with Lund University and the Steno Diabetes Center with a focus on Type I diabetes. In the long term, the possibilities for cross-border cooperation on Type II diabetes will also be explored, and Malmö University intends to contribute in this regard with, among other things, research on prevention.

• ReproUnion — continued collaboration.

• E-health — this will involve researchers from the Internet of Things and People.

The strengthen collaboration with the Medicon Valley Alliance will be evaluated after three years.

Text: Charlotte Löndahl Bechmann